Chandan Healthcare LtdQ1 FY27
Chandan Healthcare Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹222P/E: 23.1Market Cap: ₹606 CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 1
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
4 of 5 growth signals are positive — a strong management growth story.
Full analysisRevenue guidance
Category 1- →The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment.
- →Expansion from 3 to 15 states supports this growth, with several centers and labs under construction, expected to be operational within months.
- →Franchise business is a key growth driver, targeting over 1,000 franchises this year and aiming for 3,000 in three years, potentially achieving the target earlier.
- →Corporate, government, and B2C businesses are all expected to grow, with an aim for an approximate revenue mix of one-third each among B2C (franchise), B2B, and B2G segments to sustain healthy growth and margins.
- →Comprehensive diagnostic centers and labs are expected to contribute significantly, with mature centers crossing INR10 crore annual revenue and franchise volumes increasing sample inflow.
Margin guidance
Category 3- →The company targets over 50% year-on-year top-line growth for the next three years, driven by extensive expansion across India.
- →EBITA margin is expected to improve, with diagnostic EBITDA already at 36%, aiming to reach 40% within a few months.
- →PAT (Profit After Tax) is anticipated to show consistent quarter-on-quarter growth, though exact future margins are not currently specified.
- →The diagnostic business has been the primary focus after divesting the pharmacy segment, ensuring focused growth in core operations.
- →Franchise model contribution is expected to increase significantly, benefiting from high margins (around 60%+).
- →Expansion in comprehensive diagnostic centers and labs will further support profitable growth.
- →Conservative projections are given, but management is confident of achieving or exceeding targets ahead of schedule.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company mentioned they can go for debt if required to fund expansion plans.
- →No specific current fundraising through debt or equity is disclosed.
- →Internal accruals will primarily fund ongoing investments, including INR10+ crore planned capex.
- →They have no reservations about taking debt if needed to complete expansion.
- →No mentions of planned equity fundraising during the call.
Order book
YesThe transcript does not explicitly mention the current or expected order book or pending orders in specific numbers. However, from the discussion, the following points related to ongoing and upcoming business can be inferred:
- The company has secured 8 out of 12 radiology centers in Punjab, expected to be operational in the next 2-3 months.
- Guwahati center's radiological services are starting this month, with full services to begin in the next three months.
- Government projects and new comprehensive diagnostic centers will be fully operational within the current financial year.
- Expansion includes opening 8 comprehensive centers and multiple labs, including two PET scans and a genome lab, by December 2026.
- Franchise network scaled rapidly to 375 in four months, with plans to reach 1000 franchises.
- Association with Jeena Sikho covering 80% centers with samples contributing significantly to revenue.
No exact order book figure is disclosed, but operations and expansions are actively underway, indicating a strong pipeline.
Capex plans
Yes- →Major part of the current year's capex has already been invested, including acquisition of one center in April and ongoing construction of comprehensive diagnostic centers and labs.
- →Plans to open eight comprehensive centers and more than five to six labs, along with two PET scans and one genome lab, to be completed before December 2026.
- →Total additional capex expected of around INR 10 crores+, to be funded from internal accruals or debt if needed.
- →No capital investment required for franchise model; franchisees invest their own capital (~INR 1 lakh) for computer and equipment, paying initial franchise fee (INR 25,000 to 1 lakh) to the company.
- →Company’s strategic focus is on expanding diagnostics business, divesting pharmacy business to focus capital on diagnostics.
- →The franchise business is expected to grow rapidly, with zero capex from the company and advance payments received from franchisees.
How does Chandan Healthcare Ltd rank vs peers in Healthcare Services?
Pro feature1Chandan Healthcare Ltd
Rev 1Mar 3
See full Healthcare Services sector rankings
How does Chandan Healthcare Ltd rank in Healthcare Services?
Compare Chandan Healthcare Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.